ClinicalTrials.gg
RecruitingNCT06876064PROMESS_1Updated Oct 1, 2026

National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis

An observational study in Rheumatoid Arthritis (RA), sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by University Hospital, Montpellier · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier — 6 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · University Hospital, Montpellier.

Planned enrollment
8th of 12
150 · median 182
Started
2025
the only one that year
Observational
12 of 27
3 open now
Registered
26th of 27
by date

Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is the only one that started in 2025, is one of 12 observational ones, and was the 26th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

6 of the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, or all of them as a file.
02

Study summary

PROMESS 1 is a multicenter cohort interventional study aiming at analyzing the factors associated with the risk of developing clinical arthritis among exposures or combinations of exposures in patients at risk of rheumatoid arthritis (RA), as they have high levels of anti-citrullinated peptides autoantibodies (ACPA ≥2 N).

The primary endpoint is the occurrence of clinical arthritis confirmed by ultrasound at two years of following for the subject's groups at risk of RA.

This may be explained by the following exposures or combinations of exposures: smoking, occupational exposure, physical activity, diet, hormonal exposure, drug exposure, trauma and psychological stress.

Other factors may also explain the occurrence of clinical arthritis:

  • Other symptoms
  • Comorbidities, medical history, drug exposures
  • Current biology: ACPA levels, rheumatoid factor levels and isotypes, CRP levels at baseline, etc.
  • Ultrasound and MRI abnormalities.
Read the detailed description

This is a multicenter interventional cohort study. The goal of this cohort is to analyze the factors associated with the risk of developing clinical arthritis, considering individual or combined exposures, in patients at high risk of rheumatoid arthritis (RA).

Four groups of adults will be included:

  • Group 1: 50 subjects at very high risk of RA: ACPA≥2 N or (ACPA>N and rheumatoid factor≥2 N) + presence of clinically suspicious arthralgia (CSA criteria ≥4)
  • Group 2: 50 subjects at high risk of RA: ACPA≥2 N or (ACPA>N and rheumatoid factor≥2 N) without clinically suspicious arthralgia (CSA criteria \<4)
  • Group 3: 25 asymptomatic subjects, 1st degree relatives of subjects with RA (negative controls)
  • Group 4: 25 patients with early RA prior to any disease-modifying therapy (positive controls) Patients in the control groups will be included based on the same age and sex as patients in the risk groups (1 \& 2) in the recruiting center.

The primary endpoint is the occurrence of clinical arthritis, confirmed by ultrasound, after two years of follow-up in the at-risk RA groups (Groups 1 \& 2).

This may be explained by the following exposures or their combinations: smoking, occupational exposure, physical activity, diet, hormonal exposure, drug exposure, trauma and psychological stress...

Other factors that may contribute to the occurrence of clinical arthritis include:

  • Clinical elements and questionnaires assessing the other symptoms of the individuals (PRO) (subjective clinical suspicion of arthralgia CSA, painful joints at inclusion, BMI, stool consistency, functional respiratory signs, etc.)
  • Comorbidities and antecedents via CNAM pathology mapping and drug exposure via data on dispensing in towns from the SNDS
  • Current biology: ACPA levels, rheumatoid factor levels and isotypes, CRP levels at baseline, etc.
  • Ultrasound and MRI abnormalities.

The controls groups (groups 3\&4) will allow for a cross-sectional analysis, comparing at-risk RA subjects with healthy individuals who share the same genetic background. They will have a single visit at baseline without follow-up.

However, the at-risk RA groups (groups 1 \& 2) will have four visits (M0, M6, M12 et M24), plus an additional visit in case of suspected arthritis. In addition to routine care examinations performed in RA risk situations, subjects will undergo blood and stool sample collection at baseline and at one year.

All subjects regardless of group, will undergo the following baseline assessments: MRI of the dominant hand or painful hand, a lactulose-mannitol absorption test (to assess intestinal permeability), hair and saliva collection, a Schirmer test, and, in some centers, an induced sputum test (to assess pulmonary mucosa). Ultrasound of the hands and feet, as well as specific questionnaires assessing the exposome, will be conducted at all visits.

Exploratory objectives: blood and pulmonary immunobiological characteristics (immunophenotyping on fresh blood in selected centers); environmental exposure assessed with partial addresses (street and city names of homes and workplaces); psychological, psychiatric and psychosomatic factors. Exploratory predictive modelling (penalized regression, random forest, gradient boosting) will complement the confirmatory analyses after database lock.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • at-risk
  • ACPA
  • Rheumatoid arthritis
  • Exposome
  • Prediction
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The patients will be recruted during consultation or hospitalization.

Eligibility criteria

Inclusion Criteria:

  • Age between 18 and 80 years old
  • Group 1: Individuals with high risk of RA (ACPA ≥ 2N or ACPA ≥ N and rheumatoid factor ≥ 2N) and clinical signs of arthralgia (CSA criteria ≥ 4).
  • Group 2: High-risk individuals (ACPA ≥ 2N or ACPA ≥ N and rheumatoid factor ≥ 2N) without clinical arthralgia (CSA criteria \< 4).
  • Group 3: First-degree relatives of RA patients (no symptoms, negative controls).
  • Group 4: Newly diagnosed untreated RA patients (ACPA ≥ 2N or ACPA ≥ N and rheumatoid factor ≥ 2N) (positive controls).

Exclusion Criteria:

  • Groupe1-2-3:

    • Presence of clinical joint swelling (synovitis) at the time of inclusion and previously noted by a doctor
  • All groups:

    • Taking current or past background treatment for RA, even for another indication
    • therapy ≥10 mg at baseline and in the previous week
    • Presence of another connective tissue disease (Sjögren's, dermatomyositis, scleroderma, Sharp syndrome, etc.)
    • Subject unable to read and/or write
    • Inability to follow the patient during the study period
    • Failure to obtain consent
    • Non-affiliation to a social security scheme,
    • Persons placed under legal protection, under curatorship or under guardianship
    • Pregnant or breastfeeding women
    • Person participating in another intervention research including an
    • exclusion period still in progress
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1

    A total of 50 subjects will be recruited: individuals with ACPA≥2 N and clinically suspect arthralgia (CSA criteria ≥4) or those with ACPA≥N and rheumatoid factor≥2N along with clinically suspect arthralgia (CSA criteria ≥4). These subjects have an estimated 50% risk of progression to RA within 2 years.

    Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Diagnostic Test: Dental panoramic X-ray · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability. · Behavioral: Behavioral: semi-structured psychological interview (1 h, teleconsultation)

  • Group 2

    A total of 50 subjects will be recruited: individuals with ACPA≥2 N who do not meet the criteria for clinically suspect arthralgia (CSA criteria \<4) or those with ACPA≥N and rheumatoid factor≥2N who also do not meet the criteria for clinically suspect arthralgia (CSA criteria \<4). These subjects have an estimated 30% risk of progression to RA within 2 years.

    Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Diagnostic Test: Dental panoramic X-ray · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability. · Behavioral: Behavioral: semi-structured psychological interview (1 h, teleconsultation)

  • Group 3

    A total 25 subjects will be recruited: asymptomatic subjects (CSA criteria \<4) with a family history of RA in a first-degree relative (negative controls).

    Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability.

  • Group 4

    A total of 25 subjects will be recruited: individuals with RA diagnosed at polyarthritis onset (diagnosis \<6 months) who have not yet been treated, with ACPA≥2 N or ACPA≥N and rheumatoid factor≥2N (positive controls).

    Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Diagnostic Test: Dental panoramic X-ray · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability.

Interventions

  • BiologicalBlood test

    A total of 90 ml of blood will be collected while fasting, using the following tubes: one PAXGene Blood RNA Tube, one PAXGene Blood DNA Tube, five 5 mL serum tubes, five 5 mL EDTA tubes and one 2 mL EDTA tube for microbiota DNA analysis.

  • BiologicalUrine test

    Urine will be collected, while fasting and after the administration of lactulose/ mannitol to assess intestinal permeability.

  • Otherstool collection

    Stool samples will be collected either at the hospital or at home using a dedicated kit.

  • Othersaliva collection

    5 ml of saliva will be collected and saliva microbiome DNA will be collected using an OMNIgene Oral kit.

  • OtherInduced expectoration

    inhalation of salbutamol, measurement of peak expiratory flow by screening spirometry (15 min later), inhalation of a hypertonic aerosol for 3 periods of 7 min. At the end of each inhalation period, the induced sputum is collected and the peak expiratory flow is measured to prevent possible bronchospasms

  • OtherHair and nails sampling

    Hair and nails samples will be collected.

  • OtherSchirmer test

    To assess of tear secretion

  • RadiationUltrasound of hands and feet

    To assess the risk of RA in high-risk subjects by evaluating for synovitis, tenosynovitis, or intermetatarsal-phalangeal bursitis.

  • RadiationMRI Contrast

    MRI of the dominant or painful hand will be performed to assess the risk of RA in high-risk subjects.

  • OtherPatient questions

    Self-questionnaires will assess factors such as ethnic origin, family history of RA, diet, physical activity, exposure to toxic substances, pollution, occupational exposures, psychological and clinical factors.

  • Diagnostic testDental panoramic X-ray

    Performed as part of routine care to assess dental health

  • OtherConsultation with a psychologist in certain centers

    The short-CTQ will be completed during this consultation, only in centers offering consultations with a psychologist.

  • OtherMeasurement of heart rate variability.

    The patient will wear a belt throughout the visit 1. At the end of the day, the heart rate variability data measured by the belt will be recorded in the CRF (RR interval, heart rate variability SDNN, RMSSD, and LF/HF sympathovagal balance).

  • BehavioralBehavioral: semi-structured psychological interview (1 h, teleconsultation)

    At W0 on V1 an affective touch perception test (15 min), self-assessment of perceived RA risk, satisfaction and impact questionnaire. at week 26, optionally completed by an in-person session (self-drawing, Rorschach test, Thematic Apperception Test; 1 h)

06

What researchers measure

Primary outcomes

  1. Risk of developing clinical arthritis

    To analyze the factors associated with the risk of developing clinical arthritis confirmed by ultrasound among exposures or combinations of exposures in patients at high risk of RA.

    Time frame: From the baseline to the end of the follow-up at 2 years

Secondary outcomes

  1. Quantitative difference in Food Frequency Questionnaire (FFQ) between the 4 groups of subjects included, varying from never or rarely to daily or multiple times per day.

    Time frame: At baseline

  2. Quantitative difference in National Observatory for Physical Activity and Sedentariness -Physical Activity Questionnaire (ONAPS-PAQ) expressed in MET (Metabolic Equivalent of Task) per week between the 4 groups of subjects included.

    Time frame: At baseline

  3. Quantitative difference in patient-reported exposure outcome Alcohol and Substance Involvement Screening Test (ASSIST) score between the 4 groups of subjects included.

    The score varies from 0 to 36 to each substance with higher score indicates greater substance-related risk and the need for stronger intervention strategies.

    Time frame: At baseline

  4. Quantitative difference in Fagerström Test for Nicotine Dependence (FTND) score between the 4 groups of subjects included.

    The score varies from 1 to 6 with higher score indicate greater nicotine dependence.

    Time frame: At baseline

  5. Compare the exposure to pollution between the 4 groups of subjects included. "Exposure to pollution will be assessed by cross-referencing residential addresses with the Chimère database.

    Time frame: At baseline

  6. Qualitative difference in a self-report integrated questionnaire for diagnosis of all functional gastrointestinal disorders in adults between the 4 groups of subjects included.

    Time frame: At baseline

  7. Quantitative difference in patient-reported Francis score for Irritable Bowel Syndrome (IBS) between the 4 groups of subjects included.

    The score varies from 0 to 100 with higher score means severe IBS.

    Time frame: At baseline

  8. Qualitative difference in patient-reported clinical outcome of Sleep Apnea (Berlin questionnaire) between the 4 groups of subjects included.

    It is composed of 3 categories of questions, if 2 or more categories are positive it means a high risk of apnea.

    Time frame: At baseline

  9. Quantitative difference in Visual Analog Scale (VAS) score for patient's pain between the 4 groups of subjects included.

    The score varies from 0 to 100 with higher score means worst pain possible.

    Time frame: At baseline

  10. Quantitative difference in Visual Analog Scale (VAS) score for patient's fatigue between the 4 groups of subjects included.

    The score varies from 0 to 100 with higher score means extreme fatigue.

    Time frame: At baseline

  11. Quantitative difference in Visual Analog Scale (VAS) score for patient's disease activity between the 4 groups of subjects included.

    The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity).

    Time frame: At baseline

  12. Quantitative difference in Visual Analog Scale (VAS) score for disease activity on the opinion of the physician between the 4 groups of subjects included.

    The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity).

    Time frame: At baseline

  13. Quantitative difference in Pichot Fatigue Scale score between the 4 groups of subjects included.

    The score varies from 0 to 32 with higher score means severe fatigue.

    Time frame: At baseline

  14. Quantitative difference in State-Trait Anxiety Inventory (STAI) score between the 4 groups of subjects included.

    The score varies from 20 to 80 with higher score means high anxiety.

    Time frame: At baseline

  15. Quantitative difference in patient-reported outcome Posttraumatic Stress Disorder Checklist (PCL-5) score between the 4 groups of subjects included,

    The score varies from 0 to 80 with higher score means very severe symptoms (Likely posttraumatic stress disorder (PTSD)).

    Time frame: At baseline

  16. Quantitative difference in patient-reported outcome heath survey Short Form-12 (SF-12) version 2 with Physical Component Summary (PCS) and Mental Component Summary (MCS) scores between the 4 groups of subjects included

    The mean is 50 for each score with a standard deviation of 10, a higher score means better health status.

    Time frame: At baseline

  17. Quantitative difference in Insomnia Severity Index (ISI) score between the 4 groups of subjects included

    The score varies from 0 to 28 with higher score means Severe insomnia.

    Time frame: At baseline

  18. Quantitative difference in Pain Catastrophizing Scale (PCS) score between the 4 groups of subjects included

    The score varies from 0 to 52 with higher score means High pain catastrophizing.

    Time frame: At baseline

  19. Quantitative difference in Rheumatoid factor (FR) auto-antibody level between the 4 groups of subjects included.

    Expressed in IU/ml (International Units per Milliliter)

    Time frame: At baseline

  20. Quantitative difference Anti-Citrullinated Peptide Antibodies (ACPA) level between the 4 groups of subjects included.

    Expressed in IU/ml (International Units per Milliliter).

    Time frame: At baseline

  21. Quantitative difference in C-reactive protein (CRP) level between the 4 groups of subjects included.

    Expressed in mg/L (milligram per liter)

    Time frame: At baseline

  22. Quantitative difference in Neutrophils values between the 4 groups of subjects included.

    Expressed in cells/µL (microliter)

    Time frame: At baseline

  23. Quantitative difference in lymphocytes values between the 4 groups of subjects included.

    Expressed in cells/µL (microliter)

    Time frame: At baseline

  24. Quantitative difference in Platelets (PLT) between the 4 groups of subjects included.

    Expressed in platelets/µL (microliter)

    Time frame: At baseline

  25. Clinical arthritis and Clinically Suspected Arthralgias (CSA).

    Assess the incidence of clinical arthritis in high-risk RA patients overall (group 1 and 2) and in subgroups according to the presence or absence of CSA and the auto-antibody profile at inclusion. The clinical arthritis is detected by the presence of joints swelling in at least 1 of the 44 joints swelling and confirmed by ultrasound.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  26. Quantitative difference in Visual Analog Scale (VAS) score for patient's pain between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 100 with higher score means worst pain possible. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  27. Quantitative difference in Visual Analog Scale (VAS) score for patient's fatigue between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 100 with higher score means extreme fatigue. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  28. Quantitative difference in Visual Analog Scale (VAS) score for patient's disease activity between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity). Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  29. Quantitative difference in Visual Analog Scale (VAS) score for disease activity on the opinion of the physician between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity). Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  30. Quantitative difference in Pichot Fatigue Scale score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 32 with higher score means severe fatigue. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  31. Quantitative difference in State-Trait Anxiety Inventory (STAI) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 20 to 80 with higher score means high anxiety. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  32. Quantitative difference in patient-reported outcome Posttraumatic Stress Disorder Checklist (PCL-5) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 80 with higher score means very severe symptoms (Likely posttraumatic stress disorder (PTSD). Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  33. Quantitative difference in patient-reported outcome heath survey Short Form-12 (SF-12) version 2 with Physical Component Summary (PCS) and Mental Component Summary (MCS) scores between the patients who developed clinical arthritis during the 2-year f

    The mean is 50 for each score and a standard deviation of 10, a higher score means better health status. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  34. Quantitative difference in Insomnia Severity Index (ISI) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 28 with higher score means Severe insomnia. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  35. Quantitative difference in Pain Catastrophizing Scale (PCS) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    The score varies from 0 to 52 with higher score means High pain catastrophizing. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26; week 52 and week 104 visit

  36. Quantitative difference in tender joints count between the patients who developed clinical arthritis during the 2-year follow-up and those who did not, among 44 joints across the body.

    The score varies from 0 to 44 with higher score means more active inflammatory joint disease. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  37. Quantitative difference in tenosynovitis count between the patients who developed clinical arthritis during the 2-year follow-up and those who did not, among 16 flexor and extensor finger's tendons.

    The score varies from 0 to 44 with higher score means more active inflammatory joint disease. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  38. Quantitative difference in difficulties of making a fist between the patients who developed clinical arthritis during the 2-year follow-up and those who did not. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  39. Quantitative difference in tenosynovitis between the patients who developed clinical arthritis during the 2-year follow-up and those who did not detected by ultrasound. Relate this outcome to the risk of developing clinical arthritis

    Time frame: Baseline, week 26; week 52 and week 104 visit

  40. Quantitative difference in Rheumatoid factor (FR) auto-antibody level between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Expressed in IU/ml (International Units per Milliliter).Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  41. Quantitative difference in Anti-Citrullinated Peptide Antibodies (ACPA) level between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Expressed in IU/ml (International Units per Milliliter) Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  42. Quantitative difference in C-reactive protein (CRP) level between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Expressed in mg/L (milligram per liter) Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  43. Quantitative difference in Neutrophils values between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Expressed in cells/µL (microliter).Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  44. Quantitative difference in lymphocytes values between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Expressed in cells/µL (microliter). Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  45. Quantitative difference in Platelets (PLT) between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Expressed in platelets/µL (microliter), Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  46. Proportion of patients with ultrasound synovitis in the 2 groups at high-risk of rheumatoid factor (RA) (group 1 and 2).

    Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations, between the patients who developed clinical arthritis during the 2-year follow-up and those who did not. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  47. Proportion of patients with ultrasound tenosynovitis in the 2 groups at high-risk of rheumatoid factor (RA) (group 1 and 2).

    Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations, between the patients who developed clinical arthritis during the 2-year follow-up and those who did not. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline, week 26, week 52 and week 104 visit

  48. Proportion of patients with ultrasound synovitis in the 4 groups of subjects included.

    Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  49. Proportion of patients with ultrasound tenosynovitis in the 4 groups of subjects included.

    Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  50. Quantitative difference in synovitis between the 4 groups of subjects included.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  51. Quantitative difference in bone oedemes between the 4 groups of subjects included.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  52. Quantitative difference in pinch between the 4 groups of subjects included.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  53. Quantitative difference in erosion between the 4 groups of subjects included.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  54. Quantitative difference in tenosynovitis between the 4 groups of subjects included, between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  55. Quantitative difference in synovitis between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  56. Quantitative difference in bone oedemes between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  57. Quantitative difference in pinch between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  58. Quantitative difference in erosion between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  59. Quantitative difference in tenosynovitis between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.

    Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.

    Time frame: Baseline

  60. Analyzing heart rate variability as a risk factor for developing RA

    Measurement of heart rate variability in high-risk patients (group 1 + group 2) for RA

    Time frame: Baseline

  61. Analyze environmental factors associated with the risk of developing clinical arthritis.

    Exposure will be assessed using partial addresses

    Time frame: Baseline, week 26, week 52 and week 104 visit

Other outcomes

  1. Association between comorbidities and medical history

    (CNAM pathology mapping) and drug exposure (SNDS dispensing data) and the risk of clinical arthritis in Groups 1 and 2." Time frame: SNDS linkage at end of study.

    Time frame: From the baseline to the end of the follow-up at 2 years

  2. Association between psychological, psychiatric and psychosomatic factors

    (BDI, MAIA, QSSP, TAS-20, Cambridge Depersonalization Scale, DES, psychological pain VAS, RFQ-B, affective touch perception test) and the risk of clinical arthritis in Groups 1 and 2, and comparison between groups.

    Time frame: baseline, week 26, week 52 and week 104, depending on the instrument.

  3. Association between blood and pulmonary immunobiological characteristics

    (immunophenotyping on fresh blood, induced sputum) and the risk of clinical arthritis in Groups 1 and 2

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 50 months is above that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Dec 2027 → Dec 2029 and completion Dec 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Mar 14, 2025
StartActual
Oct 7, 2025
Primary completionEst.
Dec 2029was Dec 2027
CompletionEst.
Dec 2029was Dec 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
CHU Montpellier is now Recruiting
Oct 1, 2026
Primary completion
Dec 2027→Dec 2029
Oct 1, 2026
Study completion
Dec 2027→Dec 2029
Oct 1, 2026
Interventions
Added Behavioral: Behavioral: semi-structured psychological interview (1 h, teleconsultation)
Oct 1, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • Addedother outcomeAssociation between comorbidities and medical historyTime frame: From the baseline to the end of the follow-up at 2 years
  • Addedother outcomeAssociation between psychological, psychiatric and psychosomatic factorsTime frame: baseline, week 26, week 52 and week 104, depending on the instrument.
  • Addedother outcomeAssociation between blood and pulmonary immunobiological characteristicsTime frame: baseline
Oct 1, 2026
Contact
Study contact changed: c•••@chu-montpellier.fr · •••2787→c•••@chu-montpellier.fr · •••2787. See the current contact
Oct 1, 2026
Sponsor
Collaborators added: Université Paris Cité·Hôpital Européen Marseille·University of Montpellier - Inserm 1046 - PhyMeddExp·Aix Marseille Université
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    CHU Montpellier is now Recruiting
    Primary completion Dec 2027→Dec 2029
    Study completion Dec 2027→Dec 2029
    Secondary outcomes 3 added
    What changed in the outcomes
    • Addedother outcomeAssociation between comorbidities and medical historyTime frame: From the baseline to the end of the follow-up at 2 years
    • Addedother outcomeAssociation between psychological, psychiatric and psychosomatic factorsTime frame: baseline, week 26, week 52 and week 104, depending on the instrument.
    • Addedother outcomeAssociation between blood and pulmonary immunobiological characteristicsTime frame: baseline
    Interventions Added Behavioral: Behavioral: semi-structured psychological interview (1 h, teleconsultation)
    Sponsor Collaborators added: Université Paris Cité·Hôpital Européen Marseille·University of Montpellier - Inserm 1046 - PhyMeddExp·Aix Marseille Université
    Contact Study contact changed: c•••@chu-montpellier.fr · •••2787→c•••@chu-montpellier.fr · •••2787. See the current contact
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06876064
Collaborators
Nantes University Hospital, Assistance Publique Hopitaux De Marseille, University of New Orleans, Bicetre Hospital, Saint Antoine University Hospital, Groupe Hospitalier Pitie-Salpetriere, University Hospital, Brest, Assistance Publique - Hôpitaux de Paris, University Hospital, Bordeaux, Hôpital Cochin, Université Paris Cité, Hôpital Européen Marseille, University of Montpellier - Inserm 1046 - PhyMeddExp, Aix Marseille Université
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Oct 7, 2025
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

CLAIRE IMMEDIATO DAIEN, PROFESSOR
Contact
c-daien@chu-montpellier.fr
00 33 6 85 40 27 87

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion